---
title: "Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291602677.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-02T09:22:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291602677.md)
  - [en](https://longbridge.com/en/news/291602677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291602677.md)
generator: "portal-rs"
---

# Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir](https://longbridge.com/en/news/298763671.md)
- [Aptar Pharma to support Aceso’s inhaled cystic fibrosis candidate’s advance](https://longbridge.com/en/news/298273759.md)
- [Snap Could Be 23% Undervalued As New Ad Tools And Leadership Lift Optimism](https://longbridge.com/en/news/298812469.md)
- [PINS: AI-driven shopping and advertising innovations fuel growth, with Gen Z and global expansion as priorities](https://longbridge.com/en/news/298484042.md)
- [Pinterest CEO: AI Shopping Push Drives Gen Z Growth, Ad Gains](https://longbridge.com/en/news/298776824.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**